Cardiac Sarcoidosis
Conditions
Brief summary
The purpose of this study is to see if Tc 99m Tilmanocept SPECT/CT imaging can be used to identify cardiac sarcoidosis.
Interventions
150 mcg containing 10 mCi of Tc 99m tilmanocept will be administered through an IV route of injection. SPECT-CT imaging will then be performed.
Sponsors
Duke University
Foundation for Sarcoidosis Research
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Cohort 1: 1. The participant has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures. 2. Women of reproductive potential must have a negative urine pregnancy test at the time of the study. 3. The participant is at least 18 years of age. 4. The participant has a histological diagnosis sarcoidosis and meets 2014 HRS, 2014 WASOG, or 2016 JCS criteria for cardiac sarcoidosis. 5. The participant has had a clinically indicated cardiac PET-CT showing cardiac activity in the past 14 days. 6. The participant has had a prior cardiac MRI with delayed enhancement in pattern consistent with cardiac sarcoidosis as defined in the AHA Scientific Statement on the Diagnosis and Management of Cardiac Sarcoidosis (2024). Cohort 2: 1. The participant has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures. 2. Women of reproductive potential must have a negative urine pregnancy test at the time of the study. 3. The participant is at least 18 years of age. 4. Cardiac sarcoidosis has been clinically excluded. 5. The participant has an arrhythmogenic, non-ischemic cardiomyopathy defined as the presence of a cardiomyopathy with a history of recurrent (more than 1 episode) ventricular tachycardia, atrial arrhythmias, high grade AV block not due to ischemic heart disease
Exclusion criteria
1. The participant is pregnant or lactating. 2. The participant size or weight is not compatible with imaging per the investigator. 3. The participant has renal insufficiency as demonstrated by a glomerular filtration rate of \< 30 mL/min. 4. The participant has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase \[SGPT\]) or AST (aspartate aminotransferase \[SGOT\]) greater than 3 times the upper limit of normal. 5. The participant has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation. 6. The participant has a known allergy to or has had an adverse reaction to dextran exposure. 7. The participant has received an investigational product within 30 days prior to the Tc 99m tilmanocept administration (Day 0). 8. The participant has received any radiopharmaceutical within 7 days or 10 half-lives prior to the administration of Tc 99m tilmanocept (Day 0).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between the cardiac segments with tilmanocept uptake and the cardiac segments with fluorodeoxyglucose (FDG) uptake on cardiac PET-CT. For each imaging modality, a standard 17-segment cardiac model will be used. | At the time of the scan (Baseline) |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between TUVmax from tilmanocept imaging and SUVmax from FDG-PET imaging. | At the time of the scan (Baseline) |
| Correlation between the cardiac segments with tilmanocept uptake and the cardiac segments with hyperenhancement on cardiac MRI. For each imaging modality, a standard 17-segment cardiac model will be used. | At the time of the scan (Baseline) |
| Correlation of extracardiac sites with tilmanocept uptake and FDG uptake attributed to sarcoidosis. | At the time of the scan (Baseline) |
| Difference in percentage of segments with tilmanocept uptake in cohort 1 compared to cohort 2 | At the time of the scan (Baseline) |
| Adverse events, identified through clinical laboratory results (hematology, serum chemistry, vital signs). | 1 year |
| Difference in biodistribution measured by cardiac uptake relative to liver uptake | Baseline |
| Difference in biodistribution measured by uptake of the upper extremity musculature | Baseline |
Countries
United States
Contacts
CONTACTShaheela Fnu
PRINCIPAL_INVESTIGATORRavi Karra, MD
Duke Health
Outcome results
None listed